Opportunity ID: 254631
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-DP14-1407 |
| Funding Opportunity Title: | Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 4 |
| Posted Date: | May 02, 2014 |
| Last Updated Date: | May 09, 2014 |
| Original Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Current Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Archive Date: | Jul 17, 2014 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $150,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility Information
1. Eligible Applicants: Government Organizations: • State or their bona fide agents (includes the District of Columbia) 2. Special Eligibility Requirements: All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center for Chronic Disease Prevention and Health Promotion and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention |
| Description: | This FOA will allow for the development or expansion of state-based programs to promote applications of evidence-based breast and ovarian cancer genomics best practices through education, surveillance, and policy/systems change. Activities will focus on Hereditary Breast and Ovarian Cancer, but may also include Lynch Syndrome. Several system, policy, provider, and individual level barriers make the appropriate identification and treatment of high risk individuals difficult and this FOA will support state efforts to address these barriers and impact breast and ovarian cancer incidence rates. Funded applicants will develop, enhance, and evaluate education, surveillance, and policy activities related to promotion of breast and ovarian cancer genomics. These activities should take advantage of collaborations between funded applicants and partners, both internal (e.g. cancer registry, comprehensive cancer) and external (e.g., academic medical centers, non-profits, clinical genetics sites). Expected outcomes include the improvement of public and provider knowledge of hereditary cancers, genetic counseling, genetic testing, and associated clinical services, the assessment of the burden of hereditary cancers and use of genetic counseling, genetic testing and associated clinical services, and the improvement in access to and coverage of genetic counseling, genetic testing and associated clinical services for high risk individuals. Women with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations have a substantially higher breast and ovarian cancer risk than those without such mutations, with a cumulative risk of developing breast and ovarian cancer up to 57 percent and 40 percent respectively. Women with a personal or family cancer history indicative of a BRCA 1/2 mutation may benefit from genetic counseling and testing. For those who test positive, interventions including chemoprevention, enhanced surveillance or prophylactic mastectomy and oophorectomy can decrease breast cancer incidence and ovarian cancer incidence by up to 95% and 80%, respectively. The United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), have evidence-based recommendations for genetic counseling and testing for hereditary breast and ovarian cancer. People with Lynch syndrome have a higher likelihood of developing colorectal and other (e.g., gastric, endometrial, and ovarian) cancers. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity and mortality in relatives. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Procurement and Grants Office
(PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 E-mail: pgotim@cdc.gov Email:pgotim@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| . | May 09, 2014 | |
| Jun 18, 2016 | ||
| . | May 09, 2014 | |
| . | May 09, 2014 | |
| May 05, 2014 |
DISPLAYING: Synopsis 4
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-DP14-1407 |
| Funding Opportunity Title: | Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 4 |
| Posted Date: | May 02, 2014 |
| Last Updated Date: | May 09, 2014 |
| Original Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Current Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Archive Date: | Jul 17, 2014 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $350,000 |
| Award Floor: | $150,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility Information
1. Eligible Applicants: Government Organizations: • State or their bona fide agents (includes the District of Columbia) 2. Special Eligibility Requirements: All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center for Chronic Disease Prevention and Health Promotion and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention |
| Description: | This FOA will allow for the development or expansion of state-based programs to promote applications of evidence-based breast and ovarian cancer genomics best practices through education, surveillance, and policy/systems change. Activities will focus on Hereditary Breast and Ovarian Cancer, but may also include Lynch Syndrome. Several system, policy, provider, and individual level barriers make the appropriate identification and treatment of high risk individuals difficult and this FOA will support state efforts to address these barriers and impact breast and ovarian cancer incidence rates. Funded applicants will develop, enhance, and evaluate education, surveillance, and policy activities related to promotion of breast and ovarian cancer genomics. These activities should take advantage of collaborations between funded applicants and partners, both internal (e.g. cancer registry, comprehensive cancer) and external (e.g., academic medical centers, non-profits, clinical genetics sites). Expected outcomes include the improvement of public and provider knowledge of hereditary cancers, genetic counseling, genetic testing, and associated clinical services, the assessment of the burden of hereditary cancers and use of genetic counseling, genetic testing and associated clinical services, and the improvement in access to and coverage of genetic counseling, genetic testing and associated clinical services for high risk individuals. Women with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations have a substantially higher breast and ovarian cancer risk than those without such mutations, with a cumulative risk of developing breast and ovarian cancer up to 57 percent and 40 percent respectively. Women with a personal or family cancer history indicative of a BRCA 1/2 mutation may benefit from genetic counseling and testing. For those who test positive, interventions including chemoprevention, enhanced surveillance or prophylactic mastectomy and oophorectomy can decrease breast cancer incidence and ovarian cancer incidence by up to 95% and 80%, respectively. The United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), have evidence-based recommendations for genetic counseling and testing for hereditary breast and ovarian cancer. People with Lynch syndrome have a higher likelihood of developing colorectal and other (e.g., gastric, endometrial, and ovarian) cancers. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity and mortality in relatives. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Procurement and Grants Office
(PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 E-mail: pgotim@cdc.gov Email:pgotim@cdc.gov |
DISPLAYING: Forecast 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-DP14-1407 |
| Funding Opportunity Title: | Enhancing Cancer Genomics Practices through Education, Surveillance and Policy |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 6 |
| Assistance Listings: | 93.945 — Assistance Programs for Chronic Disease Prevention and Control |
| Cost Sharing or Matching Requirement: | No |
| Version: | Forecast 1 |
| Posted Date: | Jun 18, 2016 |
| Last Updated Date: | Mar 20, 2014 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | – |
| Archive Date: | – |
| Estimated Total Program Funding: | $7,500,000 |
| Award Ceiling: | $400,000 |
| Award Floor: | $300,000 |
Eligibility
| Eligible Applicants: | State governments |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | – |
| Description: | Support for Genomics practices and policies to assist State Health Departments in Cancer Prevention and Control. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
–
Email:ZKN5@CDC.GOV |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-DP14-1407 |
| Funding Opportunity Title: | Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | May 09, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Archive Date: | Jul 17, 2014 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | $150,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility Information
1. Eligible Applicants: Government Organizations: • State or their bona fide agents (includes the District of Columbia) 2. Special Eligibility Requirements: All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center for Chronic Disease Prevention and Health Promotion and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention |
| Description: | This FOA will allow for the development or expansion of state-based programs to promote applications of evidence-based breast and ovarian cancer genomics best practices through education, surveillance, and policy/systems change. Activities will focus on Hereditary Breast and Ovarian Cancer, but may also include Lynch Syndrome. Several system, policy, provider, and individual level barriers make the appropriate identification and treatment of high risk individuals difficult and this FOA will support state efforts to address these barriers and impact breast and ovarian cancer incidence rates. Funded applicants will develop, enhance, and evaluate education, surveillance, and policy activities related to promotion of breast and ovarian cancer genomics. These activities should take advantage of collaborations between funded applicants and partners, both internal (e.g. cancer registry, comprehensive cancer) and external (e.g., academic medical centers, non-profits, clinical genetics sites). Expected outcomes include the improvement of public and provider knowledge of hereditary cancers, genetic counseling, genetic testing, and associated clinical services, the assessment of the burden of hereditary cancers and use of genetic counseling, genetic testing and associated clinical services, and the improvement in access to and coverage of genetic counseling, genetic testing and associated clinical services for high risk individuals. Women with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations have a substantially higher breast and ovarian cancer risk than those without such mutations, with a cumulative risk of developing breast and ovarian cancer up to 57 percent and 40 percent respectively. Women with a personal or family cancer history indicative of a BRCA 1/2 mutation may benefit from genetic counseling and testing. For those who test positive, interventions including chemoprevention, enhanced surveillance or prophylactic mastectomy and oophorectomy can decrease breast cancer incidence and ovarian cancer incidence by up to 95% and 80%, respectively. The United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), have evidence-based recommendations for genetic counseling and testing for hereditary breast and ovarian cancer. People with Lynch syndrome have a higher likelihood of developing colorectal and other (e.g., gastric, endometrial, and ovarian) cancers. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity and mortality in relatives. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Procurement and Grants Office
(PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 E-mail: pgotim@cdc.gov Email:pgotim@cdc.gov |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-DP14-1407 |
| Funding Opportunity Title: | Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 09, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Archive Date: | Jul 17, 2014 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | $150,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility Information
1. Eligible Applicants: Government Organizations: • State or their bona fide agents (includes the District of Columbia) 2. Special Eligibility Requirements: All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center for Chronic Disease Prevention and Health Promotion and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention |
| Description: | This FOA will allow for the development or expansion of state-based programs to promote applications of evidence-based breast and ovarian cancer genomics best practices through education, surveillance, and policy/systems change. Activities will focus on Hereditary Breast and Ovarian Cancer, but may also include Lynch Syndrome. Several system, policy, provider, and individual level barriers make the appropriate identification and treatment of high risk individuals difficult and this FOA will support state efforts to address these barriers and impact breast and ovarian cancer incidence rates. Funded applicants will develop, enhance, and evaluate education, surveillance, and policy activities related to promotion of breast and ovarian cancer genomics. These activities should take advantage of collaborations between funded applicants and partners, both internal (e.g. cancer registry, comprehensive cancer) and external (e.g., academic medical centers, non-profits, clinical genetics sites). Expected outcomes include the improvement of public and provider knowledge of hereditary cancers, genetic counseling, genetic testing, and associated clinical services, the assessment of the burden of hereditary cancers and use of genetic counseling, genetic testing and associated clinical services, and the improvement in access to and coverage of genetic counseling, genetic testing and associated clinical services for high risk individuals. Women with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations have a substantially higher breast and ovarian cancer risk than those without such mutations, with a cumulative risk of developing breast and ovarian cancer up to 57 percent and 40 percent respectively. Women with a personal or family cancer history indicative of a BRCA 1/2 mutation may benefit from genetic counseling and testing. For those who test positive, interventions including chemoprevention, enhanced surveillance or prophylactic mastectomy and oophorectomy can decrease breast cancer incidence and ovarian cancer incidence by up to 95% and 80%, respectively. The United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), have evidence-based recommendations for genetic counseling and testing for hereditary breast and ovarian cancer. People with Lynch syndrome have a higher likelihood of developing colorectal and other (e.g., gastric, endometrial, and ovarian) cancers. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity and mortality in relatives. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Procurement and Grants Office
(PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 E-mail: pgotim@cdc.gov Email:pgotim@cdc.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-DP14-1407 |
| Funding Opportunity Title: | Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.283 — Centers for Disease Control and Prevention_Investigations and Technical Assistance |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 05, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jun 17, 2014 Dates:
1. Letter of Intent (LOI) Deadline: May 19, 2014 3. Informational conference call for potential applicants: May 12, 2014 at 2:00p.m.; call number 1-(877) 601-5563 Participant Code: 6130030 |
| Archive Date: | Jul 17, 2014 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | $300,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility Information
1. Eligible Applicants: Government Organizations: • State or their bona fide agents (includes the District of Columbia) 2. Special Eligibility Requirements: All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center for Chronic Disease Prevention and Health Promotion and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements. |
Additional Information
| Agency Name: | Centers for Disease Control and Prevention |
| Description: | This FOA will allow for the development or expansion of state-based programs to promote applications of evidence-based breast and ovarian cancer genomics best practices through education, surveillance, and policy/systems change. Activities will focus on Hereditary Breast and Ovarian Cancer, but may also include Lynch Syndrome. Several system, policy, provider, and individual level barriers make the appropriate identification and treatment of high risk individuals difficult and this FOA will support state efforts to address these barriers and impact breast and ovarian cancer incidence rates. Funded applicants will develop, enhance, and evaluate education, surveillance, and policy activities related to promotion of breast and ovarian cancer genomics. These activities should take advantage of collaborations between funded applicants and partners, both internal (e.g. cancer registry, comprehensive cancer) and external (e.g., academic medical centers, non-profits, clinical genetics sites). Expected outcomes include the improvement of public and provider knowledge of hereditary cancers, genetic counseling, genetic testing, and associated clinical services, the assessment of the burden of hereditary cancers and use of genetic counseling, genetic testing and associated clinical services, and the improvement in access to and coverage of genetic counseling, genetic testing and associated clinical services for high risk individuals.
Women with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations have a substantially higher breast and ovarian cancer risk than those without such mutations, with a cumulative risk of developing breast and ovarian cancer up to 57 percent and 40 percent respectively. Women with a personal or family cancer history indicative of a BRCA 1/2 mutation may benefit from genetic counseling and testing. For those who test positive, interventions including chemoprevention, enhanced surveillance or prophylactic mastectomy and oophorectomy can decrease breast cancer incidence and ovarian cancer incidence by up to 95% and 80%, respectively. The United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN), have evidence-based recommendations for genetic counseling and testing for hereditary breast and ovarian cancer. People with Lynch syndrome have a higher likelihood of developing colorectal and other (e.g., gastric, endometrial, and ovarian) cancers. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity and mortality in relatives. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDC Procurement and Grants Office
(PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 E-mail: pgotim@cdc.gov Email:pgotim@cdc.gov |
Related Documents
Packages
| Agency Contact Information: | CDC Procurement and Grants Office (PGO) Technical Information Management Section (TIMS) Phone: 770-488-2700 E-mail: pgotim@cdc.gov Email: pgotim@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.283 | NCCDPHP-NR | NCCDPHP-NR | PKG00196075 | May 02, 2014 | Jun 17, 2014 | View |
Package 1
Mandatory forms
Optional forms
Share This Post, Choose Your Platform!
About the Author: osnqt
